Zacks Research Brokers Increase Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Zacks Research boosted their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a research note issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the company will earn ($1.33) per share for the quarter, up from their prior forecast of ($1.77). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.27) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.40) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at $0.29 EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($0.24) EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The firm had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million.

A number of other equities analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Axsome Therapeutics in a report on Thursday, March 6th. Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They set a “buy” rating and a $176.00 price objective for the company. Wells Fargo & Company increased their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Mizuho increased their target price on shares of Axsome Therapeutics from $195.00 to $212.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 26th. Finally, StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $167.36.

Axsome Therapeutics Price Performance

NASDAQ:AXSM opened at $121.91 on Friday. The company has a 50-day moving average of $112.25 and a 200-day moving average of $98.88. The company has a market capitalization of $5.94 billion, a price-to-earnings ratio of -20.35 and a beta of 1.00. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. BVF Inc. IL lifted its position in shares of Axsome Therapeutics by 32.7% in the fourth quarter. BVF Inc. IL now owns 1,388,064 shares of the company’s stock worth $117,444,000 after purchasing an additional 342,064 shares in the last quarter. FMR LLC increased its holdings in Axsome Therapeutics by 20.6% during the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after buying an additional 185,951 shares during the last quarter. Geode Capital Management LLC increased its holdings in Axsome Therapeutics by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock worth $77,228,000 after buying an additional 4,079 shares during the last quarter. Wellington Management Group LLP increased its holdings in Axsome Therapeutics by 1.1% during the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after buying an additional 8,125 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Axsome Therapeutics by 10.8% during the fourth quarter. Invesco Ltd. now owns 692,464 shares of the company’s stock worth $58,589,000 after buying an additional 67,285 shares during the last quarter. Institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 22.40% of the stock is owned by insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.